Organisation paid for research Program year 2025 Source: CMS Open Payments

Ent and Allergy Partners

Neither a doctor nor a teaching hospital

Research payments

$232,512

129 payments

Through program year 2025, Ent and Allergy Partners is reported as receiving $232,512 in research payments, across 129 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $12,785 1
2024 Research $65,179 2
2023 Research $106,145 75
2022 Research $48,402 51

Breakdown

Who paid Research payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $160,942 5 payments
  2. Regeneron Pharmaceuticals, Inc. $71,571 124 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT $160,942 5 payments
  2. Assessing Long-Term Outcomes of DUPIXENT Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA) $53,401 109 payments
  3. Registry of Asthma Patients Initiating DUPIXENT (RAPID) $18,170 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record